EYLEA® (aflibercept) Injection 2 mg (0.05mL)

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Macular Neovascularization Secondary to Age-Related Macular Degeneration

Drug Information

Target Indication

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Clinical Trial

Last updated: 1/8/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

FDMT

4D Molecular Therapeutics, Inc.

Related Pipeline

Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular (Wet) Age-Related Macular Degeneration

Diabetic Macular Edema

X-Linked Retinitis Pigmentosa

Fabry Disease